214 related articles for article (PubMed ID: 9739487)
1. Paraoxonase and coronary heart disease.
Mackness MI; Mackness B; Durrington PN; Fogelman AM; Berliner J; Lusis AJ; Navab M; Shih D; Fonarow GC
Curr Opin Lipidol; 1998 Aug; 9(4):319-24. PubMed ID: 9739487
[TBL] [Abstract][Full Text] [Related]
2. Low serum paraoxonase: a risk factor for atherosclerotic disease?
Mackness MI; Durrington PN; Ayub A; Mackness B
Chem Biol Interact; 1999 May; 119-120():389-97. PubMed ID: 10421475
[TBL] [Abstract][Full Text] [Related]
3. Human serum paraoxonase.
Mackness B; Durrington PN; Mackness MI
Gen Pharmacol; 1998 Sep; 31(3):329-36. PubMed ID: 9703197
[TBL] [Abstract][Full Text] [Related]
4. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification.
Mackness B; Mackness MI; Arrol S; Turkie W; Durrington PN
FEBS Lett; 1998 Feb; 423(1):57-60. PubMed ID: 9506841
[TBL] [Abstract][Full Text] [Related]
5. Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls.
Mackness B; Durrington PN; Boulton AJ; Hine D; Mackness MI
Eur J Clin Invest; 2002 Apr; 32(4):259-64. PubMed ID: 11952811
[TBL] [Abstract][Full Text] [Related]
6. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression.
Suehiro T; Nakamura T; Inoue M; Shiinoki T; Ikeda Y; Kumon Y; Shindo M; Tanaka H; Hashimoto K
Atherosclerosis; 2000 Jun; 150(2):295-8. PubMed ID: 10856521
[TBL] [Abstract][Full Text] [Related]
7. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?
Mackness B; Davies GK; Turkie W; Lee E; Roberts DH; Hill E; Roberts C; Durrington PN; Mackness MI
Arterioscler Thromb Vasc Biol; 2001 Sep; 21(9):1451-7. PubMed ID: 11557671
[TBL] [Abstract][Full Text] [Related]
8. The gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in italian patients.
Ombres D; Pannitteri G; Montali A; Candeloro A; Seccareccia F; Campagna F; Cantini R; Campa PP; Ricci G; Arca M
Arterioscler Thromb Vasc Biol; 1998 Oct; 18(10):1611-6. PubMed ID: 9763534
[TBL] [Abstract][Full Text] [Related]
9. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon.
Mackness B; Mackness MI; Arrol S; Turkie W; Durrington PN
Br J Pharmacol; 1997 Sep; 122(2):265-8. PubMed ID: 9313934
[TBL] [Abstract][Full Text] [Related]
10. Paraoxonase activity in two healthy populations with differing rates of coronary heart disease.
MacKness B; Mackness MI; Durrington PN; Arrol S; Evans AE; McMaster D; Ferrières J; Ruidavets JB; Williams NR; Howard AN
Eur J Clin Invest; 2000 Jan; 30(1):4-10. PubMed ID: 10619995
[TBL] [Abstract][Full Text] [Related]
11. Paraoxonase and coronary heart disease.
Mackness MI; Mackness B; Durrington PN
Atheroscler Suppl; 2002 Dec; 3(4):49-55. PubMed ID: 12573363
[TBL] [Abstract][Full Text] [Related]
12. Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation.
Boemi M; Leviev I; Sirolla C; Pieri C; Marra M; James RW
Atherosclerosis; 2001 Mar; 155(1):229-35. PubMed ID: 11223446
[TBL] [Abstract][Full Text] [Related]
13. Paraoxonase, a cardioprotective enzyme: continuing issues.
Getz GS; Reardon CA
Curr Opin Lipidol; 2004 Jun; 15(3):261-7. PubMed ID: 15166781
[TBL] [Abstract][Full Text] [Related]
14. Rabbits possess a serum paraoxonase polymorphism similar to the human Q192R.
Watson CE; Draganov DI; Billecke SS; Bisgaier CL; La Du BN
Pharmacogenetics; 2001 Mar; 11(2):123-34. PubMed ID: 11266077
[TBL] [Abstract][Full Text] [Related]
15. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus.
Mackness B; Mackness MI; Arrol S; Turkie W; Julier K; Abuasha B; Miller JE; Boulton AJ; Durrington PN
Atherosclerosis; 1998 Aug; 139(2):341-9. PubMed ID: 9712341
[TBL] [Abstract][Full Text] [Related]
16. How HDL protects LDL against atherogenic modification: paraoxonase 1 and other dramatis personae.
Soran H; Schofield JD; Liu Y; Durrington PN
Curr Opin Lipidol; 2015 Aug; 26(4):247-56. PubMed ID: 26103614
[TBL] [Abstract][Full Text] [Related]
17. Does paraoxonase play a role in susceptibility to cardiovascular disease?
Aviram M
Mol Med Today; 1999 Sep; 5(9):381-6. PubMed ID: 10462749
[TBL] [Abstract][Full Text] [Related]
18. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease.
Sanghera DK; Aston CE; Saha N; Kamboh MI
Am J Hum Genet; 1998 Jan; 62(1):36-44. PubMed ID: 9443862
[TBL] [Abstract][Full Text] [Related]
19. Defective metabolism of oxidized phospholipid by HDL from people with type 2 diabetes.
Mastorikou M; Mackness M; Mackness B
Diabetes; 2006 Nov; 55(11):3099-103. PubMed ID: 17065348
[TBL] [Abstract][Full Text] [Related]
20. Paraoxonase1-192 polymorphism modulates the nonfatal myocardial infarction risk associated with decreased HDLs.
Sentí M; Tomás M; Marrugat J; Elosua R;
Arterioscler Thromb Vasc Biol; 2001 Mar; 21(3):415-20. PubMed ID: 11231922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
